|
Delayed
OTC Markets
09:51:19 2026-09-02 EDT
|
5-day change | 1st Jan Change | ||
| 0.3500 USD | 0.00% |
|
+970.34% | +133.33% |
| 03-26 | Orgenesis Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 | CI |
| 03-25 | Orgenesis Inc. Auditor Raises 'Going Concern' Doubt | CI |
| Fiscal Period: December | 2015 (USD) | 2016 (USD) | 2017 (USD) | 2018 (USD) | 2019 (USD) | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 7.65M | 35.5M | 36.02M | 530K | 1.04M | |||||
Total Revenues | 7.65M | 35.5M | 36.02M | 530K | 1.04M | |||||
Cost of Goods Sold, Total | - | - | - | 6.26M | 1.93M | |||||
Gross Profit | 7.65M | 35.5M | 36.02M | -5.72M | -893K | |||||
Selling General & Admin Expenses, Total | 18.29M | 14.71M | 15.59M | 35.13M | 14.77M | |||||
R&D Expenses | 83.99M | 36.64M | 27.07M | 10.62M | 9.62M | |||||
Amortization of Goodwill and Intangible Assets - (IS) | 478K | 948K | 911K | 721K | 728K | |||||
Other Operating Expenses | -4K | - | - | - | - | |||||
Other Operating Expenses, Total | 103M | 52.3M | 43.57M | 46.48M | 25.12M | |||||
Operating Income | -95.1M | -16.8M | -7.54M | -52.2M | -26.02M | |||||
Interest Expense, Total | -1.25M | -943K | -1.82M | -2.17M | -3.74M | |||||
Interest And Investment Income | - | - | - | - | - | |||||
Net Interest Expenses | -1.25M | -943K | -1.82M | -2.17M | -3.74M | |||||
Income (Loss) On Equity Invest. | 106K | -272K | -1.51M | -734K | -8K | |||||
Currency Exchange Gains (Loss) | -160K | -574K | -145K | -325K | -782K | |||||
Other Non Operating Income (Expenses) | 353K | 2.5M | 171K | -3K | -4.29M | |||||
EBT, Excl. Unusual Items | -96.05M | -16.09M | -10.85M | -55.43M | -34.84M | |||||
Merger & Related Restructuring Charges | -682K | - | - | - | -50K | |||||
Impairment of Goodwill | - | - | - | - | -1.21M | |||||
Gain (Loss) On Sale Of Investments | - | - | - | -699K | - | |||||
Gain (Loss) On Sale Of Assets | - | - | - | -5.34M | 5.09M | |||||
Asset Writedown | - | - | -1.06M | - | -17.13M | |||||
Other Unusual Items | - | -1.86M | -52K | -2.97M | -779K | |||||
EBT, Incl. Unusual Items | -96.74M | -17.95M | -11.96M | -64.44M | -48.92M | |||||
Income Tax Expense | -1.61M | 108K | 209K | 473K | 97K | |||||
Earnings From Continuing Operations | -95.13M | -18.06M | -12.17M | -64.92M | -49.01M | |||||
Earnings Of Discontinued Operations | 96.2M | - | - | - | - | |||||
Net Income to Company | 1.07M | -18.06M | -12.17M | -64.92M | -49.01M | |||||
Minority Interest | 39K | 6K | -2.72M | 9.56M | 848K | |||||
Net Income - (IS) | 1.11M | -18.05M | -14.89M | -55.36M | -48.16M | |||||
Preferred Dividend and Other Adjustments | -5.16M | - | - | - | - | |||||
Net Income to Common Incl Extra Items | 6.27M | -18.05M | -14.89M | -55.36M | -48.16M | |||||
Net Income to Common Excl. Extra Items | -89.93M | -18.05M | -14.89M | -55.36M | -48.16M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 2.94 | -7.44 | -5.93 | -19.08 | -11.44 | |||||
Basic EPS - Continuing Operations | -42.18 | -7.44 | -5.93 | -19.08 | -11.44 | |||||
Basic Weighted Average Shares Outstanding | 2.13M | 2.43M | 2.51M | 2.9M | 4.21M | |||||
Net EPS - Diluted | 2.94 | -7.44 | -5.93 | -19.08 | -11.44 | |||||
Diluted EPS - Continuing Operations | -42.18 | -7.44 | -5.93 | -19.08 | -11.44 | |||||
Diluted Weighted Average Shares Outstanding | 2.13M | 2.43M | 2.51M | 2.9M | 4.21M | |||||
Normalized Basic EPS | -28.14 | -4.14 | -3.79 | -8.65 | -4.97 | |||||
Normalized Diluted EPS | -28.14 | -4.14 | -3.79 | -8.65 | -4.97 | |||||
Supplemental Items | ||||||||||
EBITDA | -94.56M | -15.58M | -5.56M | -50.64M | -23.93M | |||||
EBITA | -95.26M | -16.49M | -6.63M | -51.48M | -25.29M | |||||
EBIT | -95.1M | -16.8M | -7.54M | -52.2M | -26.02M | |||||
EBITDAR | -94.01M | -15.06M | -5.02M | -50.08M | -21.69M | |||||
Total Revenues (As Reported) | 7.65M | 35.5M | 36.02M | 530K | - | |||||
Effective Tax Rate - (Ratio) | 1.66 | -0.6 | -1.75 | -0.73 | -0.2 | |||||
Deferred Foreign Taxes | - | - | - | - | - | |||||
Total Deferred Taxes | - | - | - | - | - | |||||
Normalized Net Income | -59.99M | -10.05M | -9.5M | -25.09M | -20.92M | |||||
Interest on Long-Term Debt | 1.26M | 944K | 1.83M | 2.17M | 3.74M | |||||
Supplemental Operating Expense Items | ||||||||||
Marketing Expenses | 3.48M | 577K | 474K | 464K | 1.8M | |||||
Selling and Marketing Expenses | 3.48M | 577K | 474K | 464K | 1.8M | |||||
Research And Development Expense From Footnotes | 84.18M | 36.64M | 27.19M | 10.9M | 9.98M | |||||
Net Rental Expense, Total | 547K | 514K | 546K | 561K | 2.24M | |||||
Imputed Operating Lease Interest Expense | 412K | 313K | 496K | 453K | 3.27M | |||||
Imputed Operating Lease Depreciation | 135K | 201K | 49.79K | 108K | -1.04M | |||||
Stock-Based Comp., COGS (Total) | - | - | - | 4K | 5K | |||||
Stock-Based Comp., R&D Exp. (Total) | 481K | 729K | 616K | 210K | 158K | |||||
Stock-Based Comp., SG&A Exp. (Total) | 1.92M | 945K | 362K | 249K | 191K | |||||
Stock-Based Comp., Other (Total) | 17.5M | 71K | - | - | 2.84M | |||||
Total Stock-Based Compensation | 19.9M | 1.74M | 978K | 463K | 3.19M |
- Stock Market
- Stocks
- ORGS Stock
- Financials Orgenesis Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















